Cohance Lifesciences Limited
COHANCE
Rang in aandelen
#6337
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a... Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
Aandeelprijs
$5.09
Marktkapitalisatie
$1.95B
Verandering (1 dag)
0.79%
Verandering (1 jaar)
-57.04%
Land
IN
Handel Cohance Lifesciences Limited (COHANCE)
Categorie
Healthcare
Winst voor Cohance Lifesciences Limited (COHANCE)
Winst in Jun 2025 TTM: $37.76M
Volgens de meest recente financiële verslagen van Cohance Lifesciences Limited bedraagt de huidige winst van het bedrijf $37.76M. In 2024 behaalde het bedrijf een winst van $48.65M, een daling ten opzichte van de winst van 2023, die $68.11M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Cohance Lifesciences Limited van 2019 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $37.76M | -6.11% |
| 2025 | $40.21M | -17.35% |
| 2024 | $48.65M | -28.57% |
| 2023 | $68.11M | -22.55% |
| 2022 | $87.95M | 37.66% |
| 2021 | $63.89M | 18.98% |
| 2020 | $53.70M | 136.19% |
| 2019 | $22.73M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 4,573.48% |
IN
|
